The Risk of Lymphoma Development in Autoimmune Diseases, Archives of Internal Medicine, vol.165, issue.20, pp.2337-2381, 2005. ,
DOI : 10.1001/archinte.165.20.2337
Autoimmune and Chronic Inflammatory Disorders and Risk of Non-Hodgkin Lymphoma by Subtype, JNCI Journal of the National Cancer Institute, vol.98, issue.1, pp.51-60, 2006. ,
DOI : 10.1093/jnci/djj004
Autoimmunity and Susceptibility to Hodgkin Lymphoma: A Population-Based Case-Control Study in Scandinavia, JNCI Journal of the National Cancer Institute, vol.98, issue.18, pp.1321-1351, 2006. ,
DOI : 10.1093/jnci/djj361
Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis & Rheumatism, vol.36, issue.3, pp.692-701, 2006. ,
DOI : 10.1002/art.21675
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine, Gut, vol.54, issue.8, pp.1121-1126, 2005. ,
DOI : 10.1136/gut.2004.049460
Reversible Lymphomas Associated with Epstein-Barr Virus Occurring during Methotrexate Therapy for Rheumatoid Arthritis and Dermatomyositis, New England Journal of Medicine, vol.328, issue.18, pp.1317-1338, 1993. ,
DOI : 10.1056/NEJM199305063281806
The effect of methotrexate and anti???tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation, Arthritis & Rheumatism, vol.52, issue.5, pp.1433-1442, 2007. ,
DOI : 10.1002/art.22579
Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France, Blood, vol.99, issue.11, pp.3909-3924, 2002. ,
DOI : 10.1182/blood.V99.11.3909
Anti-TNF therapy in RA and risk of malignant lymphomas Relative risks and time-trends in the Swedish Biologics Register, Ann Rheum Dis, vol.68, issue.5, 2008. ,
Tumor necrosis factor ?? antagonist use and cancer in patients with rheumatoid arthritis, Arthritis & Rheumatism, vol.14, issue.9, pp.2757-64, 2006. ,
DOI : 10.1002/art.22056
Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis & Rheumatism, vol.359, issue.6, pp.1740-51, 2004. ,
DOI : 10.1002/art.20311
Risk of tuberculosis higher with monoclonal-antibody than with soluble-receptor anti-TNF therapy in the 3-year prospective French RATIO registry, Arthritis Rheum, 2009. ,
The RATIO observatory: French registry of??opportunistic infections, severe bacterial infections, and??lymphomas complicating anti-TnF?? therapy, Joint Bone Spine, vol.72, issue.6, p.25, 2005. ,
DOI : 10.1016/j.jbspin.2005.10.004
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement, Epidemiology, vol.18, issue.6, p.296, 2007. ,
DOI : 10.1097/EDE.0b013e3181577654
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies, JAMA, vol.295, issue.19, pp.2275-85, 2006. ,
DOI : 10.1001/jama.295.19.2275
Etanercept therapy in rheumatoid arthritis and the risk of malignancies, Ann Rheum Dis, vol.67, p.12, 2008. ,
Hepatosplenic T Cell Lymphoma Associated With Infliximab Use in Young Patients Treated for Inflammatory Bowel Disease, Journal of Pediatric Gastroenterology and Nutrition, vol.44, issue.2, pp.265-272, 2007. ,
DOI : 10.1097/MPG.0b013e31802f6424
Committee for medicinal products for human use, 2008. ,
Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment, Rheumatology International, vol.311, issue.5, pp.475-482, 2008. ,
DOI : 10.1007/s00296-007-0467-6
Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment, Annals of the Rheumatic Diseases, vol.64, issue.7, pp.1098-1107, 2005. ,
DOI : 10.1136/ard.2004.026252
Effect of tumor necrosis factor alpha and infliximab on apoptosis of B lymphocytes infected or not with Epstein???Barr virus, Cytokine, vol.33, issue.6, pp.337-382, 2006. ,
DOI : 10.1016/j.cyto.2006.03.005
URL : https://hal.archives-ouvertes.fr/hal-00451195
Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists, Journal of Pharmacology and Experimental Therapeutics, vol.301, issue.2, pp.418-444, 2002. ,
DOI : 10.1124/jpet.301.2.418